News/Media

Press Releases

Fractyl Announces CE Mark Approval for Revita DMR at EASL 2016

Also presents new data in patients with type 2 diabetes and fatty liver disease WALTHAM, MA AND BARCELONA, SPAIN – April 15, 2016 – Fractyl Laboratories, Inc. (Fractyl) announced today that the Company’s Revita DMRTM System, used to perform minimally invasive duodenal...

Fractyl Announces Completion of $57 Million Series C Investment

Deerfield Capital Joins Existing Investor Group
WALTHAM, MA. – November 19, 2015 – Fractyl Laboratories, Inc. (Fractyl) today announced the extension of their $40M series C investment with $17M of additional funding. Total investment in Fractyl’s round C financing is now $57M. New investor Deerfield Management Company, L.P. joined existing investors…

Fractyl Announces Positive Results from 39-Patient Study of Revita DMR System

Significant changes in blood sugar control in patients with uncontrolled type 2 diabetes
LONDON, UK AND WALTHAM, MA. – September 28, 2015 – Fractyl Laboratories, Inc. (Fractyl) today announced results from a 39-patient, single-site, proof-of-concept study demonstrating that a minimally invasive procedure using the Revita™ Duodenal Mucosal Resurfacing™ (DMR) System produces significant, beneficial changes in blood sugar in patients with poorly controlled…

First Patients Enrolled in Multicenter Clinical Trial of Fractyl Revita DMR System

Trial will evaluate implant-free duodenal mucosal resurfacing for type 2 diabetes
WALTHAM, Mass. – July 16, 2015 – Fractyl Laboratories Inc. (Fractyl) today announced that patient enrollment has begun in a multicenter clinical trial (“Revita-1” trial) being conducted in Europe and South America to evaluate the safety and performance of the Revita™ Duodenal Mucosal Resurfacing™ (DMR) System. Revita is the first non-invasive, implant free duodenal resurfacing…

Fractyl Laboratories to Present at the Piper Jaffray 26th Annual Healthcare Conference

WALTHAM, MA – Marketwired – Nov 26, 2014 – Fractyl Laboratories Inc., the company pioneering the first procedural therapy to directly treat the underlying digestive causes of insulin resistance in patients with type 2 diabetes, will participate in the Piper Jaffray 26th Annual Healthcare Conference taking place at The New York Palace Hotel in New York City…

Fractyl Labs Announces Approval to Initiate Multicenter Clinical Trial of Revita DMR Procedure

Emergent Medical Partners Joins Existing Fractyl Investor Syndicate
WALTHAM, Mass. – January 12, 2015 – Fractyl Laboratories Inc. (Fractyl) today announced the Company has received approval to begin enrollment in a multicenter clinical trial designed to evaluate the safety and performance of the Revita™ Duodenal Mucosal Resurfacing™ (DMR) procedure, the first procedural therapy designed to directly treat the underlying digestive causes of insulin…

Fractyl Labs Announces Positive Clinical Data for First Procedural Therapy to Treat Type 2 Diabetes

Mithril Capital Management Leads $40M Series C Financing to Join Early Investors General Catalyst, Bessemer and Domain Associates
Trial Shows Revita™ Duodenal Mucosal Resurfacing™ (DMR) Procedure Dramatically Improves Glucose Control in Patients with Type 2 Diabetes

WALTHAM, Mass. – September 4, 2014 – Fractyl Laboratories Inc. today announced positive clinical data for the first procedural therapy to directly treat the underlying digestive causes of insulin resistance in patients with uncontrolled type 2 diabetes. The non-invasive Revita™ Duodenal Mucosal Resurfacing™ (DMR)…

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Fractyl disavows any obligation to update the information contained in such press releases after the date of their issuance.

Newstop

Upcoming Eventstop

Title Date Location Description

15th Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease

11/30/17 – 12/02/17

Los Angeles, CA

The Congress is the premier global meeting dedicated to diabetes, obesity, lipids, cardiovascular disease (CVD), and energy balance, and linking basic research to clinical practice.
View Conference Website